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Background: Chronic pancreatitis (CP) is a complex inflammatory disease with remarkably impaired
quality of life and permanent damage of the pancreas. This paper is part of the international consensus
guidelines on CP and presents the consensus on factors elevating the risk for CP.l Medicine, Medical School,
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TreatmentMethods: An international working group with 20 experts on CP from the major pancreas societies (IAP,
APA, JPS, and EPC) evaluated 14 statements generated from evidence on four questions deemed to be the
most clinically relevant in CP. The Grading of Recommendations Assessment, Development, and Evalu-
ation (GRADE) approach was used to evaluate the level of evidence available per statement. To determine
the level of agreement, the working group voted on the 14 statements for strength of agreement, using a
nine-point Likert scale in order to calculate Cronbach’s alpha reliability coefficient.
Results: Strong consensus and agreement were obtained for the following statements: Alcohol, smoking,
and certain genetic alterations are risk factors for CP. Past history, family history, onset of symptoms, and
life-style factors including alcohol intake and smoking history should be determined. Alcohol con-
sumption dose-dependently elevates the risk of CP up to 4-fold. Ever smokers, even smoking less than a
pack of cigarettes per day, have an increased risk for CP, as compared to never smokers.
Conclusions: Both genetic and environmental factors can markedly elevate the risk for CP. Therefore,
health-promoting lifestyle education and in certain cases genetic counselling should be employed to
reduce the incidence of CP.
© 2020 IAP and EPC. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Introduction
Chronic pancreatitis (CP) is a heterogeneous inflammatory dis-
ease, which can develop via multiple pathological mechanisms and
can have diverse clinical presentations. Frequently, recurrent acute
attacks precede CP and pain is the most disabling symptom [1].
Quality of life is remarkably impaired in CP, one third of the patients
are unable towork. For these patients, the main goal of treatment is
pain reduction since pain is the most important factor that in-
fluences the quality of life in CP [2e6]. However, in a number of
cases, CP develops silently without acute episodes and/or signifi-
cant pain, and clinical care is focused primarily at the management
of the endocrine and exocrine insufficiency [7]. CP patients without
prior acute pancreatitis appear to be significantly older and may
have distinct risk factors such as a so far unknown genetic variants.
For etiologic classification of CP, the TIGAR-O system has been most
commonly used, with etiologies categorized as toxic-metabolic,
idiopathic, genetic, autoimmune, recurrent and/or severe acute
pancreatitis-associated, and obstructive [8]. Toxic-metabolic causes
include alcohol [9e12], smoking [13,14], hypercalcemia [15e17],
hyperlipidemia [18,19], chronic renal failure [20,21], medications,
and toxins [22]. While smoking is considered an independent risk
factor for CP, a large population study indicated that alcohol can
have a bidirectional effect. Thus, moderate alcohol consumption
(less than 2 drinks per day in men) was found to be protective,
whereas heavy drinking (more than 4 drinks per day in men) was
shown to be a risk factor for CP [10,23]. These data suggest that
recording an accurate medical history is important for the identi-
fication of the correct etiology. An incorrectly applied diagnosis of
alcoholic CP may stigmatize the patient and delay the recognition
of the true disease cause [10,23]. Idiopathic cases include those
with early onset, late onset, or tropical [24]. Genetic etiology in-
cludes clinically significant, pathogenic mutations or other alter-
ations in risk genes [25,26] (in alphabetical order) CEL [27], CFTR
[28,29], CPA1 [30,31], CTRC [32], PRSS1 [33,34] and SPINK1 [35e37].
Autoimmune processes include both isolated and syndromic oc-
currences. Cases complicating recurrent or severe acute
pancreatitis-associated CP may have post-necrotic, vascular/
ischemic, or post-irradiation etiologies. Obstructive causes include
divisum, sphincter of Oddi disorders, duct obstruction, and post-
traumatic pancreatic duct scars. The M-ANNHEIM system classified
risk factors for CP into 7 categories, specifically alcohol consump-
tion (excessive >80 g/d; increased, 20e80 g/d; and moderate,
<20 g/d; nicotine consumption; nutritional factors such as calorie
derived from fat and protein, and hyperlipidemia; hereditary fac-
tors responsible for some familial, idiopathic, and tropical cases;efferent duct factors including pancreas divisum, annular pancreas,
other congenital abnormalities of the pancreas predisposing to
pancreatic duct obstruction, posttraumatic pancreatic duct scars,
and sphincter of Oddi dysfunction; autoimmune pancreatitis;
miscellaneous metabolic and toxic disorders including hypercal-
cemia, hyperparathyroidism, chronic renal failure, and drugs, or
toxins [38].
Several different treatment guidelines on CP exist [39e46],
however, there is a clear lack of consensus on the risk factors
elevating the incidence of CP. Our aim was to create a consensus
guideline that is international and multidisciplinary, from devel-
opment and early diagnosis to progression and treatment of CP.
During the EPC2016 conference the four major pancreatic societies,
namely the International Association of Pancreatology (IAP),
American Pancreatic Association (APA), Japan Pancreas Society
(JPS) and the European Pancreatic Club (EPC) have decided to
develop an evidence based management guideline on CP. Interna-
tional experts were identified to have a multidisciplinary repre-
sentationwithin subgroups focusing on 16 key topics of CP. The first
major step was the agreement on a new mechanistic definition of
CP [1].
Thereon several parts of the consensus guidelines have been
published, covering the early diagnosis of CP [1], imaging of CP [47]
and understanding and management of pain [2]. This manuscript is
another part of the international consensus guidelines, covering the
topic on risk factors in CP and is meant to guide the clinical prac-
titioners and surgeons in the treatment and education of patients
with CP.
Methods
Twenty experts on CPwere appointed. PH andMSTwere chosen
as chairs of the group. Based on a review of data from the relevant
literature all experts presented their perspectives on risk for CP. The
method of the systematic literature review has been previously
described [10]. The international experts evaluated fourteen
statements generated from evidence of the relevant literature.
Grading
The Grading of Recommendations Assessment, Development,
and Evaluation (GRADE) approach was used to evaluate the level of
evidence per statement (see http://www.uptodate.com/home/
gradingtutorial). Quality assessment of evidence was graded as
‘high’ if there was (very) low probability of further research sub-
stantially changing the conclusions, ‘moderate’ if further research
Table 1
Risk genes and alleles in chronic pancreatitis. Allele frequency and effect size are
shown for European non-alcoholic patient populations. Risk size estimates are given
for heterozygous variants unless indicated otherwise. Common haplotypes associ-
ated with chronic pancreatitis at the CLDN2, CTRB1-CTRB2 and PRSS1-PRSS2 loci are
not listed.
Gene symbol Typical variants Frequency Risk effect
PRSS1 p.N29I, p.R122H 4% >300-fold
CPA1 p.V251 M, p.N256K 3% 25-fold
SPINK1 p.N34S, c.194þ2T>C 10% 15-fold
CTRC c.180C>T (p.G60 ¼ ) homozygous 4% 10-fold
p.R254W, p.K247_R254del 2% 5-fold
CEL CEL-HYB1 hybrid allele 4% 5-fold
CFTR p.F508del, p.R117H 10% 3-fold
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research was likely to completely change the conclusions. The
strengths of the recommendation were graded as ‘strong’ if it was
very certain that benefits outweigh risks and burdens, ‘weak’ if
risks and burdens appear to be finely balanced, or when benefits,
risks, and burdens are closely balanced or uncertain, or ‘condi-
tional’ if it was in between strong and weak recommendation.
Consensus
After grading, the working group of international experts voted
on the 14 statements for strength of agreement, using a nine-point
Likert scale. Out of the results, a Cronbach’s alpha reliability coef-
ficient was calculated per statement (http://hdl.handle.net/1805/
344). The voting results were classified for agreement as either;
‘strong’ if 80% of votes were 7 or above, ‘conditional’ if 65% of votes
were 7 or above, and ‘weak’ less than 65% of votes were 7 or above.
In addition, comments to each question and statements were
compiled to explain the surrounding issues, supported by key ref-
erences. All statements and comments were reviewed by all au-
thors to ensure the general relevance and applicability of the
conclusions. Eventually a final draft of the document was generated
and circulated to all authors for final editing and approval.
Results
Q-1. What are the risk factors for CP?
Statement-1: Alcohol, smoking, and certain genetic alterations
are risk factors for CP.
Quality assessment: high; Recommendation: strong; Agreement:
strong (a ¼ 100%)
Comments
Many authors have reported alcohol to be a particularly
important risk factor. Evidence also suggests a positive association
of cigarette smoking with development of pancreatitis, indepen-
dently of alcohol. A systematic reviewandmeta-analysis based on 6
studies of a total population of 146,517 including 1,671 persons
with pancreatitis showed a smooth curve representing as approx-
imately exponential dose-response relationship between average
amount of alcohol consumed and occurrence of pancreatitis [9].
Individuals consuming 36 g of alcohol per day had a relative risk
(RR) of 1.2 (95% confidence interval or CI, 1.2e1.3) compared with
non-drinkers, while those consuming 96 g per day had a four-fold
increased risk of pancreatitis (relative risk 4.2, 95% CI, 3.1e5.7) [9]. A
case-control study in Japan showed that long-term alcohol con-
sumption for over 35 years was associated with increased risk
(odds ratio or OR ¼ 4.0) [48]. A recent meta-analysis showed that
dose-response relationships between alcohol consumption and risk
of pancreatitis were curvilinear for CP and acute pancreatitis in
men but non-linear for acute pancreatitis in women [10]. In addi-
tion, a large population-based prospective study in the USA showed
that moderate alcohol consumption (<24 ethanol g/day or <2
drinks/day) is associated with a lower risk of RAP/CP (hazard ratio
0.57, 95% CI 0.41e0.79), whereas heavy drinking (>48 ethanol g/day
or >4 drinks/day) results in elevated risk of RAP/CP (hazard ratio
1.50, 95% CI 0.94e2.39) in men.
A meta-analysis concerning smoking assessed 10 case-control
studies and 2 cohort studies concluding that tobacco smoking
may increase risk of developing CP [13]. Compared to lifelong
nonsmoker, pooled risk estimates for current smokers were 2.8
(95% CI, 1.8e4.2) overall and 2.5 (95% CI, 1.3e4.6) when data were
adjusted for alcohol consumption. In a recent systematic review
and meta-analysis examining 22 studies [49], summary relativerisks and 95% CI for CP for all subjects who ever smoked, current
smokers and former smokers respectively were 3.00 (1.46e6.17),
2.72 (1.74e4.24), and 1.27 (1.00e1.62), respectively. In a case-
control study including 241 patients, smoking was associated
with pancreatic exocrine insufficiency, (odds ratio and 95% CI, 2.4
and 1.17e5.16), calcifications (2.33 and 1.10e4.95), and major
morphologic changes (3.41 and 1.31e8.85) [50].
In a prospective long-term study of 227 patients with alcoholic
CP followed over 18 years, 54.2% were overweight before disease
onset and 15.0% were obese, compared with 37.7% (3.1%) in a
contemporary male control population. The authors concluded that
obesity may be an additional risk factor for alcoholic CP [51].
Mutations or other alterations in susceptibility genes increase
risk for both alcoholic and non-alcoholic disease [52e54]. Highly
penetrant, strong genetic variants (e.g. PRSS1 and CPA1 mutations)
may cause autosomal dominant hereditary pancreatitis, while the
majority of variants are associated with sporadic disease with no
family history. The effect size tends to be smaller for alcoholic CP.
Genetic testing should target risk genes with relatively strong ef-
fects; which currently include CEL, CFTR, CPA1, CTRC, PRSS1 and
SPINK1. Although common variants in CLDN2, an inversion at the
CTRB1-CTRB2 locus, and a variant in the PRSS1 promoter modify risk
in alcoholic and non-alcoholic disease, the small effect size and the
high frequency of these genetic changes limit their utility in
determining genetic etiology. Similarly, testing for a protective
variant in PRSS2 is not helpful clinically. A summary table of risk
genes and alleles in CP can be found in Table 1.
Frequency of progression from acute pancreatitis to CP was re-
ported in a meta-analysis where 10% of patients with a first episode
of acute pancreatitis and 36% of patients with recurrent acute
pancreatitis developed CP [55]. In a cohort study including 352
patients with acute pancreatitis, progression of pancreatitis
occurred in 85 patients during follow-up (24.1%); 48.2% of cases
becoming chronic originated as alcoholic acute pancreatitis, 47.0%
as idiopathic acute pancreatitis, and 4.8% as acute pancreatitis with
another cause. Smoking plus drinking over 20 g of alcohol was the
strongest risk factor for progression (hazard ratio, 3.18; 95% CI,
1.06e9.55) [56]. Notably, in a number of patients CP develops
without a preceding acute pancreatitis attack [7].
Autoimmune pancreatitis has been considered a risk factor for
CP. However, high-level evidence such as meta-analysis data is not
available. In a case-control study including 69 patients with auto-
immune pancreatitis, multivariate analysis identified Wirsung and
Santorini duct narrowing at diagnosis as a significant independent
risk factor for pancreatic stone formation (odds ratio, 4.4; P¼ 0.019)
[57]. Autoimmune pancreatitis indeed may progress to CP.
Pancreas divisum causing drainage impairment can be
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iate analysis identified pancreas divisum as an independent risk
factor for recurrent acute pancreatitis (odds ratio, 11.5; 95% CI,
1.6e83.3) [59].
Q-2. What should be done to determine the risk factors/etiology for
CP at the time of diagnosis?
Statement-2. Past history, family history, onset of symptoms,
and life-style factors including alcohol intake and smoking history
should be determined.
Quality assessment: high; Recommendation: strong; Agreement:
strong (a ¼ 100%)
Statement-3. Laboratory data including serum triglycerides,
calcium, IgG4, and possible morphologic abnormalities of the
pancreas including pancreas divisum might be assessed.
Quality assessment: low; Recommendation: weak; Agreement:
strong (a ¼ 89.5%)
Statement-4. In idiopathic disease, full sequence analysis of the
CFTR, CPA1, CTRC, PRSS1 and SPINK1 gene exons and exon-intron
boundaries and testing for the CEL gene pathogenic hybrid allele
is recommended in order to explore the genetic background.
Quality assessment: low; Recommendation: conditional; Agree-
ment: conditional (a ¼ 73.7%)
Comments
The etiology of CP has been considered by meta-analyses and,
alternatively, by reviews of population-based epidemiologic data;
risk of CP is multifactorial with strong likelihood of interaction
among the various factors [8,13,38]. Determination of risk factors
and etiology for CP at the time of diagnosis is important for treat-
ment and prevention of recurrence, because continuing alcohol
abuse and smoking are associated with disease progression. How-
ever, individual risk factors can be difficult to isolate, because the
factors are influenced by associations and interactions.
Alcohol has been identified as a definitive risk factor of CP [60].
Persons who drink 80 g or more of alcohol per day over 6e12 years
are at risk of developing CP [9]. Obtaining as accurate alcohol intake
history is extremely important. As smoking is another important
risk factor for CP [13], a detailed smoking history should be
obtained.
Laboratory data including serum triglycerides, calcium, and
IgG4 might be assessed at the time of diagnosis [57,61].
Morphology of the pancreas might be examined by imaging to di-
agnose pancreas divisum [59].
CP can be a genetic disease and the yield of genetic testing is
high, particularly in pediatric and early-onset cases. Genetic testing
can help with the determination of etiology and may guide thera-
peutic choices such as total pancreatectomy, which is more likely to
be performed if underlying genetic risk has been demonstrated. As
carriers of SPINK1 variants often exhibit more rapid progression;
genetic testing also has prognostic value. Patients with CFTR vari-
ants may benefit from the novel CFTR-modifying drugs once these
become available for the treatment of CP. Robust development of
sequencing technology continuously decreases costs of testing,
which should not be a limiting factor any more.
Q-3. How much alcohol consumption can be considered as risk
factor/etiology for CP?
Statement-5. Alcohol consumption dose-dependently elevates
the risk of CP. Heavy drinkers have some 5 times more chances to
develop CP than non-alcohol consumers.
Quality assessment: moderate; Recommendation: strong; Agree-
ment: strong (a ¼ 100%)Statement-6. Alcohol consumption of less than 60 g/day in-
creases the risk and promotes the progression of CP in susceptible
individuals.
Quality assessment: low; Recommendation: conditional; Agree-
ment: weak (a ¼ 63.2%)
Statement-7. Alcohol consumption of equal to or more than
60 g/day increases the risk of CP.
Quality assessment: moderate; Recommendation: strong; Agree-
ment: strong (a ¼ 100%)
Statement-8. The effects of alcohol seems to be independent of
smoking.
Quality assessment: low; Recommendation: conditional; Agree-
ment: conditional (a ¼ 73.7%)
Statement-9. Alcohol abuse increases the risk of progression
from acute pancreatitis to CP. After an acute attack of pancreatitis
almost half of alcohol abusers develop CP. Figures rise to 80% after
recurrent pancreatitis.
Quality assessment: moderate; Recommendation: strong; Agree-
ment: strong (a ¼ 89.5%)
Comments
Alcohol misuse is the most common single cause of CP and ac-
counts for approximately 45%e70% of CP cases in industrialized
nations worldwide [62]. The Zurich conference defined alcoholic CP
which developed following a daily intake of alcohol >80 g/day for
several years [63]. Only 2e5% of heavy drinkers develop pancrea-
titis [62,64]. The increased risk of CP in individuals who consume
equal to or more than 5 drinks/day has been consistently demon-
strated. The North American Pancreatitis Study-2 65 revealed a
significant association between alcohol and CP only in subjects who
consumed 5 drinks/day (odds ratio: 3.1). A population-based
cohort study in Denmark [66] showed alcohol intake of 35e48
drinks/week increased the risk of CP (Hazard ratio: 3.2). In Japanese
case-control studies [48,67], the risk of CP was higher even with a
smaller amount of alcohol. The odds ratio was 5.7 for alcohol
consumption of 50e99 g/day [6]. In another Japanese case-control
study [67], alcohol consumption of even 20~<40 g/day increased
the risk of CP compared with nondrinkers; the odds ratios for
alcohol consumption of 20~<40 g/day, 40~<60 g/day,
60~<80 g/day, 80~<100 g/day, and100 g/daywere 2.6, 3.2, 9.2,
13.0, and 19.6, respectively. A systematic review and meta-analysis
of these 4 studies [48,65e67] showed that the risk of CP increased
monotonically according to the average alcohol consumption with
no identifiable threshold (relative risks at 25 g/day ¼ 1.58, 50 g/
day ¼ 2.51, 75 g/day ¼ 3.97, and 100 g/day ¼ 6.29) [10]. One unit of
alcohol equals 10 ml or 8 g of pure (100%) ethanol. In USA, 1 drink
equals 14 g of pure (100%) ethanol or 1.75 units [65].
Although associations were similar for men and women [66,67],
susceptible women might develop alcoholic CP after a shorter
duration of alcohol consumption and lower cumulative amounts of
alcohol consumption than men [68]. Alcohol intake, even less than
50 g/day, induced earlier disease characterized by more frequent
severe pain, calcification, and complications [69].
Q4. How much smoking can be considered as risk factor/etiology for
CP?
Statement-10. Ever smokers (even smoking less than 1 pack of
cigarettes per day) have an increased risk for CP, as compared to
never smokers.
Quality assessment: moderate; Recommendation: strong; Agree-
ment: strong (a ¼ 89.5%)
Statement-11. There seems to be a dose-response effect for the
amount of daily consumption on the risk to develop CP.
Quality assessment: low; Recommendation: conditional;
Table 2
Summary of the statements.
STATEMENT QUALITY
ASSESSMENT
RECOMMENDATION AGREEMENT
(alfa%)
1. Alcohol, smoking, and certain genetic alterations are risk factors for chronic pancreatitis. high strong strong
(100%)
2. Past history, family history, onset of symptoms, and life-style factors including alcohol intake and smoking history
should be determined.
high strong strong
(100%)
3. Laboratory data including serum triglycerides, calcium, IgG4, and possible morphologic abnormalities of the
pancreas including pancreas divisum might be assessed.
low weak strong
(89.5%)
4. In idiopathic disease, full sequence analysis of the CFTR, CPA1, CTRC, PRSS1 and SPINK1 gene exons and exon-intron
boundaries and testing for the CEL gene pathogenic hybrid allele is recommended in order to explore the
etiological background.
low conditional conditional
(73.7%)
5. Alcohol consumption dose-dependently elevates the risk of CP. Heavy drinkers have some 5 times more chances
to develop chronic pancreatitis than non-alcohol consumers.
moderate strong strong
(100%)
6. Alcohol consumption of less than 60 g/day increases the risk and promotes the progression of CP in susceptible
individuals.
low conditional weak (63.2%)
7. Alcohol consumption of equal to or more than 60 g/day increases the risk of CP. moderate strong strong
(100%)
8. The effects of alcohol seems to be independent of smoking. low conditional conditional
(73.7%)
9. Alcohol abuse increases the risk of progression from acute to chronic pancreatitis. After an acute attack of
pancreatitis almost half of alcohol abusers develop CP. Figures rise to 80% after recurrent pancreatitis.
moderate strong strong
(89.5%)
10. Ever smokers (even smoking less than 1 pack of cigarettes per day) have an increased risk for CP, as compared to
never smokers.
moderate strong strong
(89.5%)
11. There seems to be a dose-response effect for the amount of daily consumption on the risk to develop CP. low conditional strong
(94.7%)
12. Risk increases with time of exposure. low conditional strong
(89.5%)
13. Risk tends to diminish with abstinence (former smokers). low conditional strong
(94.7%)
14. Risk seems to be independent of alcohol abuse. low conditional conditional
(78.9%)
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Statement-12. Risk increases with time of exposure.
Quality assessment: low; Recommendation: conditional; Agree-
ment: strong (a ¼ 89.5%)
Statement-13. Risk tends to diminish with abstinence (former
smokers).
Quality assessment: low; Recommendation: conditional; Agree-
ment: strong (a ¼ 94.7%)
Statement-14. Risk seems to be independent of alcohol abuse.
Quality assessment: low; Recommendation: conditional; Agree-
ment: conditional (a ¼ 78.9%)Comments
Accumulating and convincing evidence suggests that tobacco
smoking is independently and dose-dependently associated with
increased risk of CP [23,65,67,70e76]. The relative risk for CP in ever
smokers is 3.0 (95% CI: 1.48e6.17), in current smokers is 2.72 (95%
CI: 1.74e4.24) and in former smokers is 1.27 (95% CI: 1.00e1.62) as
compared to never smokers [49]. The number of studies investi-
gating detailed tobacco use (instead of only stating the numbers of
ever, current and former smokers), including pack-years or daily
quantity (mostly restricted tomore or less than 1 pack per day), and
CP risk are limited [23,75]. However, it seems that increasing
smoking dose and duration elevate the risk for CP development. A
meta-analysis of five studies (some of which also included the data
of acute pancreatitis and/or recurrent acute pancreatitis patients)
by Andriulli et al. [13] revealed that the relative risk of CP in current
smokers smoking less than 1 pack per day was 2.4 (95% CI, 0.9e6.6)
which increased to 3.3 (95% CI, 1.4e7.9) in those smoking 1 or more
packs per day. Another recent meta-analysis [49] of CP patients and
a large multiethnic prospective cohort of recurrent acute pancrea-
titis/CP patients [23] reported somewhat lower risk values. The
increased risk of CP due to smoking is present in both genders, but
it is more pronounced in males [75].The detrimental effect of tobacco use in CP patients is high-
lighted by the fact that smoking is associated with earlier diagnosis
of the disease and with the appearance of calcifications and dia-
betes, independent of alcohol consumption [77,78]. Furthermore,
cessation of smoking was shown to reduce the progression of CP
[74]. Therefore, the importance of smoking cessation should be
stressed in patients with CP.
Summary
The authors have reviewed, summarized and discussed the
available evidences on the risk factors for CP. Importantly, both
genetic and environmental factors were found to play crucial roles
in the development of CP. Therefore, health-promoting lifestyle
education and in certain cases genetic counselling should be
applied to reduce the incidence of CP. These evidence-based
guidelines provide the current state of the art of the risk factors
in CP. An overview of the statements is presented in Table 2.
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